3',5'-cyclic dTMP : A 3',5'-cyclic pyrimidine nucleotide derived from thymidine monophosphate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 12359154 |
| CHEBI ID | 75183 |
| SCHEMBL ID | 1619438 |
| MeSH ID | M0131897 |
| Synonym |
|---|
| 3',5'-cyclic thymidine monophosphate |
| thymidine, cyclic 3',5'-(hydrogen phosphate) |
| 6453-60-7 |
| i4n756m3gw , |
| cyclic 3',5'-dtmp |
| unii-i4n756m3gw |
| 3',5'-cyclic tmp |
| thymidine, phosphate (cyclic) |
| thymidine cyclophosphate |
| cyclic tmp |
| 3',5'-cyclic dtmp |
| cyclic 3',5'-thymidine monophosphate |
| ctmp |
| thymidine 3',5'-cyclic monophosphate |
| thymidine cyclic 3',5'-phosphate |
| thymidine 3',5'-(hydrogen phosphate) |
| CHEBI:75183 |
| cyclic 3',5'-thymidylic acid |
| SCHEMBL1619438 |
| QSJFDOVQWZVUQG-XLPZGREQSA-N |
| DTXSID80214800 |
| thymidine cyclic 3',5'-(hydrogen phosphate) |
| 2'-deoxythymidine cyclic 3',5'-(hydrogen phosphate) |
| 3',5' cyclic tmp |
| 3',5' cyclic dtmp |
| thymidine-3',5'-cyclic monophosphate |
| Q27145158 |
| 1-[(4ar,6r,7as)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-5-methylpyrimidine-2,4-dione |
| Role | Description |
|---|---|
| human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| 3',5'-cyclic pyrimidine nucleotide | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.89) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||